Please click on this link or the image above to view a recording of this webinar and learn about: Gene Therapy Breakthroughs for Cardiomyopathies.
In this webinar, Dr. Whit Tingley, Tenaya’s Chief Medical Officer, shares updates on Tenaya’s MyPEAK-1 Study for HCM due to a MYBPC3 mutation and their RIDGE-1 Trial for ARVC due to a PKP2 mutation. Dr. Tingley discusses how TN-201 and TN-401 are intended to work and shares recently announced updates on the design and status of each clinical trial.
This is an exciting webinar highlighting the advances of gene therapy for cardiomyopathies and the hope for the future.
Speaker: Whit Tingley, M.D., Ph.D., Chief Medical Officer, Tenaya Therapeutics